

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 13073

Title: Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

Reviewer code: 02456031

Science editor: Yue-Li Tian

Date sent for review: 2014-08-06 15:03

Date reviewed: 2014-09-04 15:37

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

I think the paper is a well written and comprehensive state-of-the-art review on HER2 targeted therapy in gastric cancer. I have some suggestion which might help improving the quality of the paper. Table 1. Study design: please, add information on the full study design (randomized, double-blind, parallel group, cross-over, controlled, etc.). Also add information on the duration of treatment (e.g. weeks or number of cycles, etc.) Table 2. Which is the meaning and usefulness of referring to the PMID? Please, remove this reference from the table. Conclusion and future prospects (may be "perspectives" is a better term). I would try to summarize a bit the final message. Likely, a bullet point table would help. Please, send a clear and practical message to the reader. Please, revise the English style. There are some spelling and grammatical errors, here and there. e.g. Page 4 "is belongs". Page 7 "the utilizing...". Page 14 "TRSTUZUMAB". Table 1 "preoperative".

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 13073

Title: Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

Reviewer code: 02454257

Science editor: Yue-Li Tian

Date sent for review: 2014-08-06 15:03

Date reviewed: 2014-08-30 23:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

With this manuscript the authors present a commendable task requiring great diligence on the current status of HER2 targeted therapy of gastric cancer. The considerable data is the first problem of this manuscript. It is definitely too extensive for an overview article. This manuscript does have the potential for a book chapter which is supported by the large number of 89(!) references. Furthermore, there has been a large number of publications including reviews within the last year focusing on new therapy possibilities of gastric cancer via the HER2 pathway (see especially BPG, J?rgensen JT, 2014). This is the reason why the novelty effect compared to the complexity of the manuscript is small. In my opinion the authors should focus either on the experimental results with cell lines and tumor specimen or on the clinical study data. Independents of the above the authors should put more value judgment in the conclusion and future prospects section. General statements like: "...These data will provide a rationale for developing more potent HER2 inhibitors...." do only marginally live up to the scientific demands of the authors. In the presented very extensive form the manuscript does provide insufficient new information and is therefore not suitable for publication in the World Journal of Clinical Cases.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 13073

Title: Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

Reviewer code: 02460781

Science editor: Yue-Li Tian

Date sent for review: 2014-08-06 15:03

Date reviewed: 2014-08-25 22:53

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This review is on the recent advances in the HER2 targeted therapy of gastric cancer. It is a well-written article. I recommend acceptance for publication. And I have a suggestion, it will be better if the author can add the number of the patients in each study in table one "Table 1. Clinical trials of HER2-targeted therapy in gastric cancer (after ToGA study)"

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 13073

Title: Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

Reviewer code: 00058511

Science editor: Yue-Li Tian

Date sent for review: 2014-08-06 15:03

Date reviewed: 2014-08-10 15:57

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

It is a well-written comprehensive review article on the novel biological agents opening new horizons and research efforts with promising results for gastric cancer. With great pleasure I recommend acceptance for publication.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 13073

Title: Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

Reviewer code: 02439561

Science editor: Yue-Li Tian

Date sent for review: 2014-08-06 15:03

Date reviewed: 2014-09-01 14:54

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

You did good jobs to review about target therapy for gastric cancer, which are currently hot issues. However, you need to review with time before submission your manuscript.